Although it will be negatively affected by the COVID-19 pandemic in the short term, the European aesthetic injectables market will grow rapidly through 2029, driven by increasing penetration into new patient groups, such as men and younger patients, as well as major M&As in the aesthetics space. The new advancements and products along with efforts to distinguish their products, players in this market will help the market to grow but the growth will decelerate to some extent.

This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for aesthetic injectables in Europe across a 10-year period.

The emergence of COVID-19 is affecting the aesthetic injectable market in the short term.

How will COVID-19 affect procedure volumes?

What will be the impact on market dynamics?

What strategies can companies use to remain successful in this market?

The dermal filler market has a greater revenue share in the European aesthetic injectable market.

What are the drivers and limiters of the aesthetic injectable market?

What is the variation across procedure shares and revenue shares for dermal filler and BTX market?

Major M&A activity is affecting the competitive landscape.

Which are the most notable M&As in this market and what competitive advantages have they provided to the companies involved?

What are the strategies adopted by companies to bolster their presence in Europe?

New advancements in treatments and products entering the European market are supporting the sales.

Which new products are launched in the market?

How will the advanced treatments benefit the patients?

Table of contents

  • Aesthetic Injectables - Market Insights - Europe

Author(s): Raghav Tangri, MRes

Raghav Tangri is a senior analyst within the Orthopedics, Dental, and Aesthetics Medtech Insights team at Decision Resources Group, specializing in aesthetics device markets. Raghav has been featured in the Aesthetics Journal and has participated in several white papers on policy advocacy and analysis. Raghav also has expertise in the endoscopy device space, including the markets for gastrointestinal devices, open and laparoscopic devices, and hernia repair devices. Raghav holds a Bachelor's degree in Biotechnology from Delhi Technological University and a Master's degree in Life Sciences from Imperial College London.

Follow Raghav on Twitter:@rtangri_DRG